http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2259481-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afc5d8c9ee6673323cee3e2d19bc5146 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 |
| filingDate | 1999-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ede20fe2777b0344fff4d125ebcc94c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d974ed0af00d84edb257e63e880ebbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8336021ebe7df4fe8d2968c3cf46ee19 |
| publicationDate | 2006-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2259481-T3 |
| titleOfInvention | THREE-PHASE ORAL CONTRACEPTIVE. |
| abstract | A three-phase oral contraceptive unit having 21 separate dosing units, adapted for successive daily oral administration, comprising 5-8 dosing units containing, separately or in admixture, a combination of an estrogen and a progestogen at effective contraceptive doses that they correspond in estrogenic activity to 25 microg of 17alpha-ethinylestradiol and in progestogenic activity to 0.178 mg of norgestimate as a first phase; followed by 7-11 dosage units containing, separately or in admixture, a combination of an estrogen and a progestogen at an effective contraceptive dose corresponding to estrogen activity at 25 microg of 17alpha-ethinylestradiol and in progestogenic activity at 0.215 mg of Norgestimate as a second phase; followed by 3-7 dosage units containing, separately or in admixture, a combination of an estrogen and a progestogen at an effective contraceptive dose corresponding to estrogen activity at 25 microg of 17alpha-ethinylestradiol and in progestogenic activity at 0.250 mg of Norgestimate as a third phase; and optionally containing 4-8 additional dosage units free of estrogen and progestogen; with the proviso that the dose of progestogen should increase from the first phase to the second phase to the third phase and that the estrogen dose remains constant in each phase. |
| priorityDate | 1998-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.